USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Chhattisgarh Ex-DGP Vishwa Ranjan, Architect Of ‘Green Hunt’ Policy, Critical Condition On Ventilator Support
Mumbai News: Youth Threatens Self-Immolation At Mulund Station After Rejection; Police File FIR
Navi Mumbai News: Students Participate Enthusiastically In ‘Hind-di-Chadar’ Commemoration Activities Across City
Navi Mumbai Crime Branch Busts Adulterated Cement Racket In Taloja, Fake Branded Bags Seized
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
